ClinicalTrials.gg
RecruitingNCT07332273Updated Jan 12, 2026

Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity.

A Phase 3 interventional study of Levothyroxine and Placebo in Obesity, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. Recruiting at 5 sites in Spain. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Obesity by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud — 3 open to participants now, 3 under way, 1 of them phase 3. Obesity · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud.

Planned enrollment
2nd of 10
286 · median 91
Started
2025
the only one that year
Phase 3
2 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Obesity by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 3, and was the 9th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 11 studies in Obesity by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 25 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Obesity by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, or all of them as a file.
02

Study summary

Obesity is a chronic disease with high relapse rates after initial weight loss. Thyroid hormones modulate energy expenditure, body composition, and thermogenesis; higher TSH within the reference range and subclinical hypothyroidism have been associated with adverse metabolic profiles and weight gain. These signals suggest the thyroid axis could influence weight-loss response and subsequent regain. Levothyroxine (LT4) is widely used for hypothyroidism; evaluating its adjuvant role in obesity management is clinically relevant.

This is a phase III, randomized, double-blind, placebo-controlled, multicentre clinical trial conducted in five Spanish hospitals. A total of 286 adults (25-60 years) with grade I-II obesity will be enrolled if they have subclinical hypothyroidism (TSH 5-10 mIU/L with normal peripheral hormones) or are euthyroid with TSH in the highest tertile of the reference range. Participants are randomized 1:1, stratified by age, sex, and BMI.

Intervention: LT4 88 µg once daily or matching placebo for 9 months. During months 0-3, all participants receive a structured hypocaloric Mediterranean diet (≈600 kcal/day deficit; macronutrients 45% carbohydrates, 35% fats, 20% proteins) plus standardized physical-activity advice. From months 3-9, lifestyle support continues with a normocaloric Mediterranean diet. Physical-activity guidance targets ≥150 min/week of moderate-to-vigorous activity (spread over ≥3 days) and 2-3 resistance sessions/week.

Primary endpoint (3 months): change in body weight (kg and %) and body composition (BMI, waist/hip circumferences, fat mass, fat-free mass, total body water by bioimpedance) comparing LT4 versus placebo under the same lifestyle program. The study is powered for n=286.

Key secondary endpoints (up to 9 months): prevention of weight regain; changes in obesity stage; cardiometabolic markers (lipids, glucose/HbA1c, HOMA-IR, adipokines, inflammation, blood-pressure patterns); resting energy expenditure by indirect calorimetry; objectively measured physical activity by accelerometry; cardiac parameters (ECG) and safety; quality of life (EuroQol-5D). Mechanistic substudies assess adipose-tissue metabolic activity (gene/protein expression, browning markers, mitochondrial DNA) and explore gut microbiota, epigenetic signatures, nitrogen balance, and sex-specific differences in response.

Assessments are performed at baseline and follow-up visits through 9 months and include anthropometry, bioimpedance, laboratory panels, indirect calorimetry, ambulatory blood-pressure monitoring, ECG, diet/physical-activity questionnaires, and biobanking of blood, urine, and stool; an adipose-tissue biopsy is obtained in a subsample.

The trial uses intention-to-treat analyses with mixed linear models and is designed with 90% power to detect a clinically meaningful between-group difference in 3-month weight loss; total sample size is 286 (143 per arm). Overall study duration is 21 months (12 months of recruitment plus 9 months of treatment/follow-up); each participant remains in the study for 9 months.

In summary, this trial tests whether adding LT4 88 µg/day to a structured Mediterranean-diet and exercise program enhances early weight loss and helps prevent regain versus placebo in adults with obesity and high-normal TSH or subclinical hypothyroidism, while characterizing metabolic mechanisms and biomarkers of response.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 25-60 years of age.
  • Obesity grade I-II: 30.0-39.9 kg/m².
  • Either subclinical hypothyroidism (TSH 5-10 mIU/L with normal peripheral hormones) or euthyroid with TSH in the highest tertile of the population reference range (no known thyroid disease).
  • Able and willing to provide written .
  • Women of : not pregnant or breastfeeding and using a highly effective method (failure rate \<1%) per CTCG guidance (e.g., hormonal methods, IUD/IUS, sterilization, or dual barrier with spermicide).

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus ( ≥6.5%, fasting glucose ≥126 mg/dL, or 2-h OGTT ≥200 mg/dL).
  • Any prior thyroid disease (hyperthyroidism, overt hypothyroidism) or prior LT4 treatment.
  • Current or recent (≤3 months) use of levothyroxine, hypoglycaemic agents, antibiotics, or regular probiotics/prebiotics.
  • Active cancer or cancer within the last 5 years (except basal-cell carcinoma).
  • Chronic liver disease with total ≥2.0 mg/dL or >3× .
  • Established cardiovascular disease (e.g., stroke, ischemic heart disease, peripheral artery disease).
  • Atrial fibrillation or any arrhythmia history.
  • Uncontrolled hypertension (>160/100 mmHg) despite therapy (assessed by ABPM at screening).
  • Any heart failure; resting HR >85 bpm; \<60 mL/min.
  • Known , , or infection.
  • Acute inflammatory disease or inflammatory bowel disease.
  • Serious underlying disease that, in the investigator's judgment, could affect participation.
  • Drug/alcohol abuse, \<12 months, inability to follow the recommended diet or attend visits.
  • Positive pregnancy test, pregnant, expecting pregnancy, or breastfeeding.
  • to any component of the product.
  • Inability or unwillingness to provide .
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
286 participants (estimated)

Study arms

  • Experimental
    Levothyroxine 88mcg

    Drug: Levothyroxine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugThyroxineStudies of ThyroxineThyroxine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Film-coated oral tablets containing levothyroxine 88 mcg, taken once daily for 9 months. All participants receive a structured lifestyle program: months 0-3 hypocaloric Mediterranean diet (\~600 kcal/day deficit) with physical-activity advice; months 3-9 normocaloric Mediterranean diet with continued advice. The IMP is purchased from authorized manufacturers, then reconditioned and relabeled per GMP and supplied blinded for the full study period. Dispensing follows the randomization code; emergency unblinding only via the hospital pharmacy. Store per label (do not store above 25 °C); adherence assessed by pill count and self-report.

  • DrugPlacebo

    (white, plain, circular), oral once daily for 9 months, no active ingredient. Administered alongside the same lifestyle program as the active arm (months 0-3 hypocaloric Mediterranean diet; months 3-9 normocaloric Mediterranean diet). Placebo is reconditioned and relabeled per GMP to be indistinguishable from levothyroxine; supply is blinded and dispensed per randomization code. Emergency unblinding is performed only by the pharmacy service when medically necessary.

06

What researchers measure

Primary outcomes

  1. Change in body weight (kg) from baseline to Month 3

    Time frame: Baseline to Month 3 (12 weeks ±2)

  2. Change in fat mass (kg) by bioimpedance from baseline to Month 3

    Time frame: Baseline to Month 3 (12 weeks ±2)

Secondary outcomes

  1. Weight-regain (kg) from Month 3 to Month 9

    Time frame: Month 3 to Month 9 (36 weeks ±2)

  2. Change in BMI (kg/m²) from baseline to Month 9

    Time frame: Baseline to Month 9

  3. Change in waist circumference (cm) from baseline to Month 9

    Time frame: Baseline to Month 9

  4. Change in fasting LDL-cholesterol (mg/dL) from baseline to Month 9

    Time frame: Baseline to Month 9

  5. Change in glycaemic control (HbA1c, %) from baseline to Month 9

    Time frame: Baseline to Month 9

  6. Change in insulin resistance (HOMA-IR) from baseline to Month 9

    Time frame: Baseline to Month 9

  7. Change in resting energy expenditure (kcal/day) by indirect calorimetry from baseline to Month 9

    Time frame: Baseline to Month 9

  8. Change in physical activity level measured by accelerometry

    Physical activity will be quantified by accelerometry using the ActiGraph WGT3X-BT device, worn for 7 consecutive days before and after the intervention periods, as specified in the protocol.

    Time frame: Baseline to Month 9

  9. Change in blood pressure parameters assessed by ambulatory blood pressure monitoring (ABPM) from baseline to Month 9

    Ambulatory blood pressure monitoring (24-hour ABPM) will be performed to register possible blood pressure adverse events, as specified in the protocol.

    Time frame: Baseline to Month 9

  10. Change in heart rate measured by electrocardiogram (ECG) from baseline to Month 9

    Cardiac evaluation will be performed by electrocardiogram (ECG). Minimum, maximum and average heart rates will be assessed as specified in the protocol.

    Time frame: Baseline to Month 9

  11. Change in number of ventricular extrasystoles measured by electrocardiogram (ECG) from baseline to Month 9

    The number of ventricular extrasystoles will be assessed by electrocardiogram (ECG) during cardiac evaluation, according to the protocol.

    Time frame: Baseline to Month 9

  12. Change in QT interval measured by electrocardiogram (ECG) from baseline to Month 9

    QT interval will be evaluated by electrocardiogram (ECG) as part of the cardiac assessment described in the protocol.

    Time frame: Baseline to Month 9

  13. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: From first dose to Month 9

  14. Change in quality of life measured by EuroQol-5D index from baseline to Month 9

    Time frame: Baseline to Month 9

  15. Change in quality of life measured by EuroQol-5D visual analogue scale (VAS) from baseline to Month 9

    Time frame: Baseline to Month 9

  16. Change in gene expression related to metabolic activity in adipose tissue (subsample)

    Gene expression changes in adipose tissue samples related to lipogenic and lipolytic capacity, adipokines, thyroid receptor and browning biomarkers will be analyzed, as described in the protocol.

    Time frame: Baseline to Month 3

  17. Change in protein abundance related to metabolic activity in adipose tissue (subsample)

    Protein abundance changes in adipose tissue samples related to metabolic activity will be evaluated according to the protocol.

    Time frame: Baseline to Month 3

  18. Change in mitochondrial DNA in adipose tissue (subsample)

    Mitochondrial DNA in adipose tissue samples will be analyzed as part of the metabolic activity assessment described in the protocol.

    Time frame: Baseline to Month 3

  19. Change in gut microbiota diversity determined by 16S rRNA gene sequencing from baseline to Month 9

    Time frame: Baseline to Month 9

  20. Change in relative abundance of gut microbiota taxa determined by 16S rRNA gene sequencing from baseline to Month 9

    Time frame: Baseline to Month 9

  21. Change in nitrogen balance (g/day) from baseline to Month 9

    Time frame: Baseline to Month 9

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the published results and the data dictionary will be made available to the scientific community via institutional repositories, following FAIR principles and Spanish/EU data protection law (LOPD 3/2018; GDPR). Participants are informed about data use and re-use; personal identifiers are removed and study data are stored on encrypted, password-protected servers. Access will be provided after primary results publication, subject to a reasonable request and a data use agreement consistent with GDPR; supporting documents (protocol, SAP, blank CRFs) and code will also be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's planned 12 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Jan 12, 2026
StartActual
Nov 5, 2025
Primary completionEst.
Nov 2026
CompletionEst.
May 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07332273
Lead sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Nov 5, 2025
Primary completion
Nov 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thyroxine

Start the discussion